Shigellosis is an infectious disease caused by a group of bacteria called Shigella. It primarily affects the digestive system and is a common cause of diarrhea, especially in children.
There’s no licensed Shigella vaccine available for general use yet, but the race is on—and it’s heating up.
Recently , Bharat Biotech has partnered with GSK plc for the development of a vaccine for Shigellosis.
News from :
What are your opinions on this ? Do you think they’ll be successful ?
Seems like a very nice initiative. But like they themselves mentioned, antimicrobial resistance has to be kept in mind and as a prevention modality, it’s giving good hope.
Given Bharat Biotech’s track record and GSK’s global expertise, this partnership holds real promise. If clinical trials go well, it could be a game-changer for preventing childhood diarrheal deaths in low-resource settings.
Given Bharat Biotech’s track record and GSK’s global expertise, this partnership holds real promise. If clinical trials go well, it could be a game-changer for preventing childhood diarrheal deaths in low-resource settings!!